News & Updates
Filter by Specialty:
Vedolizumab lowers risk of severe CDI in patients with ulcerative colitis
Treatment with vedolizumab is associated with a reduced adjusted risk of severe Clostridioides difficile infection (CDI), but not total CDI, in patients with ulcerative colitis (UC), reports a study. Additionally, cytomegalovirus colitis (CMVC) is not seen in those who initiated vedolizumab.
Vedolizumab lowers risk of severe CDI in patients with ulcerative colitis
25 Jul 2023
Does ribavirin improve efficacy of SOF/VEL/VOX in HCV retreatment?
The combination of sofosbuvir, velpatasvir, and voxilaprevir (SOF/VEL/VOX) with or without ribavirin demonstrates efficacy for the retreatment of patients with hepatitis C virus (HCV) infection in whom prior direct-acting antiviral (DAA) treatment has failed, a study in Egypt has shown.
Does ribavirin improve efficacy of SOF/VEL/VOX in HCV retreatment?
24 Jul 2023
Prolonged-release pirfenidone shows therapeutic potential in post–COVID-19 pulmonary fibrosis
A 3-month course of prolonged-release pirfenidone formulation appears to be safe and efficacious in the treatment of patients with postacute sequelae of COVID-19 (PASC)-pulmonary fibrosis, as shown in a study.
